This reading material is for future delegates:
- Patient preferences for managing disability in multiple sclerosis – Measuring the condition with a thousand faces
A report by The Economist Intelligence Unit - Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis
Scolding N, et al. Pract Neurol 2015;15:273–279. - Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group
Rieckmann p, et al. Mult Scler Relat Disord 2015;4,202–218. - Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Giovannoni G, et al. Mult Scler Relat Disord 2015;4,329–333. - How long is the presymptomatic phase of multiple sclerosis?
Giovannoni G. Mult Scler Relat Disord 2016; 7,12–13. - Brain health: time matters in multiple sclerosis
Giovannoni G, et al. Mult Scler Relat Disord 2016;9,S5–S48. - Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses
Giovannoni G, et al. Mult Scler Relat Disord 2017;12,70–78. - Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson AJ, et al. Lancet Neurol 2017;17:2,162-173. - Medicine and the McNamara fallacy
J R Coll Physicians Edinb 2017; 47: 281–7